Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07464756

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

A Prospective Exploratory Study of SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Conditions Gastric Adenocarcinoma

Interventions S-1 & Oxaliplatin SHR-1701 apatinib

Updated 1 time since 2026 Last updated: Mar 8, 2026 Started: Apr 5, 2026 Primary completion: May 31, 2028 Completion: Jul 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gastric Adenocarcinoma and is currently actively recruiting participants. The First Affiliated Hospital with Nanjing Medical University leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital with Nanjing Medical University

Data source: The First Affiliated Hospital with Nanjing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.